The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.
Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.
Jeuveau, an aesthetic-only neurotoxin, was evaluated in 2 US Phase 3 placebo-controlled trials and a European and Canadian Phase 3 head-to-head trial vs onabotulinumtoxinA (Botox Cosmetic; Allergan).
In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12.
An expert panel assessed 41 diets to come up with their final results, examining the evidence behind each diet’s claims, the short-term and long-term weight loss associated with the diet, how easy the diet is to follow, how well each diet conforms to current nutrition standards, and its effect on diabetes and cardiovascular disease prevention.
Using data from the 2011 to 2016 National Vital Statistics System-Mortality files, the authors conducted a literal text analysis of death certificates to identify drugs mentioned as contributing to the cause of overdose death.
To investigate the link between organic food consumption and cancer risk, study authors conducted a population-based prospective cohort study among French adults.
Ilumya has been made available by Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis.
The approval of Bryhali was based on data from 2 randomized, double-blind studies conducted in 430 patients with moderate to severe plaque psoriasis.
Participants who responded to a question related to rosacea diagnosis in 2005 were included in the final analysis (N=82,737).
